Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease

被引:175
作者
Bermejo, Paloma [1 ]
Martin-Aragon, Sagrario [1 ]
Benedi, Juana [1 ]
Susin, Cristina [1 ]
Felici, Ernanuela [1 ]
Gil, Pedro [2 ]
Ribera, Jose Manuel [2 ]
Villar, Angel M. [1 ]
机构
[1] Univ Complutense Madrid, Fac Farm, Dept Farmacol, E-28040 Madrid, Spain
[2] Hosp Univ Clin San Carlos, Serv Geriatr, Madrid 28040, Spain
基金
新加坡国家研究基金会;
关键词
mild cognitive impairment; Alzheimer's disease; peripheral inflammatory markers; IL-6; TNF-alpha; IFN-alpha; COX-2;
D O I
10.1016/j.imlet.2008.02.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple pathogenic factors may contribute to the pathophysiology of Alzheimer's disease (AD). Peripheral markers have been used to assess biochemical alterations associated with AD and mild cognitive impairment (MCI) involved in its pathophysiology. The present study was conducted to evaluate inflammatory peripheral markers in elderly patients with MCI, patients with AD and normal elderly subjects. We measured plasma levels of different cytokines (IL-6, TNF-alpha and IFN-alpha) and platelet levels of cyclooxigenase-2 (COX-2) from 34 patients with MCI, 45 patients with AD and 28 age-matched control subjects. MCI and AD patients showed similarities in TNF-alpha and COX-2 levels, and differences in IL-6 and INF-alpha. Whereas augmented IL-6 levels have been found in AD patients, a significant increase in INF-alpha has been detected only in patients with MCI possibly associated with the depression stage frequently found in cognitive impairment. In conclusion, inflammatory response may be an early factor in AD development and these changes in circulating markers are possibly related to the progression of MCI to AD. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:198 / 202
页数:5
相关论文
共 66 条
  • [1] Inflammation and Alzheimer's disease
    Akiyama, H
    Barger, S
    Barnum, S
    Bradt, B
    Bauer, J
    Cole, GM
    Cooper, NR
    Eikelenboom, P
    Emmerling, M
    Fiebich, BL
    Finch, CE
    Frautschy, S
    Griffin, WST
    Hampel, H
    Hull, M
    Landreth, G
    Lue, LF
    Mrak, R
    Mackenzie, IR
    McGeer, PL
    O'Banion, MK
    Pachter, J
    Pasinetti, G
    Plata-Salaman, C
    Rogers, J
    Rydel, R
    Shen, Y
    Streit, W
    Strohmeyer, R
    Tooyoma, I
    Van Muiswinkel, FL
    Veerhuis, R
    Walker, D
    Webster, S
    Wegrzyniak, B
    Wenk, G
    Wyss-Coray, T
    [J]. NEUROBIOLOGY OF AGING, 2000, 21 (03) : 383 - 421
  • [2] Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease
    Angelis, P
    Scharf, S
    Mander, A
    Vajda, F
    Christophidis, N
    [J]. NEUROSCIENCE LETTERS, 1998, 244 (02) : 106 - 108
  • [3] Beyond the global score of the Zarit Burden Interview: useful dimensions for clinicians
    Ankri, J
    Andrieu, S
    Beaufils, B
    Grand, A
    Henrard, JC
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 20 (03) : 254 - 260
  • [4] Role of inflammation and cellular stress in brain injury and central nervous system diseases
    Barone, Frank C.
    Kilgore, Kenneth S.
    [J]. CLINICAL NEUROSCIENCE RESEARCH, 2006, 6 (05) : 329 - 356
  • [5] Platelet APP isoform ratios in asymptomatic young adults expressing an AD-related presenilin-1 mutation
    Baskin, F
    Rosenberg, RN
    Iyer, L
    Schellenberg, GD
    Hynan, L
    Nee, LE
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 183 (01) : 85 - 88
  • [6] INTERLEUKIN-6 AND ALPHA-2-MACROGLOBULIN INDICATE AN ACUTE-PHASE STATE IN ALZHEIMERS-DISEASE CORTICES
    BAUER, J
    STRAUSS, S
    SCHREITERGASSER, U
    GANTER, U
    SCHLEGEL, P
    WITT, I
    YOLK, B
    BERGER, M
    [J]. FEBS LETTERS, 1991, 285 (01) : 111 - 114
  • [7] Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment
    Bermejo, Paloma
    Martin-Aragon, Sagrario
    Benedi, Juana
    Susin, Cristina
    Felici, Emanuela
    Gil, Pedro
    Ribera, Jose Manuel
    Villar, Angel Ma
    [J]. FREE RADICAL RESEARCH, 2008, 42 (02) : 162 - 170
  • [8] Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system
    Bonaccorso, S
    Marino, V
    Puzella, A
    Pasquini, M
    Biondi, M
    Artini, M
    Almerighi, C
    Verkerk, R
    Meltzer, H
    Maes, M
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (01) : 86 - 90
  • [9] Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms
    Bonaccorso, S
    Puzella, A
    Marino, V
    Pasquini, M
    Biondi, M
    Artini, M
    Almerighi, C
    Levrero, M
    Egyed, B
    Bosmans, E
    Meltzer, HY
    Maes, M
    [J]. PSYCHIATRY RESEARCH, 2001, 105 (1-2) : 45 - 55
  • [10] Role of complement in neurodegeneration and neuroinflammation
    Bonifati, Domenico Marco
    Kishore, Uday
    [J]. MOLECULAR IMMUNOLOGY, 2007, 44 (05) : 999 - 1010